ERBB2 and breast carcinoma: Furthermore, the network meta-analysis results involving 13 studies [12,22,21,[26], [28], [29], [30], [31], [32], [33],35,34,37] demonstrated that Ribociclib + ET can significantly improve the OS of patients with HR+/HER2-breast cancer, exhibiting statistical differences compared with ET alone (P < 0.05).